Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v15-FR Version v5-FR
Language French French
Date Updated 2021-01-14 2019-08-29
Drug Identification Number 02226383 02226383
Brand name TEVA-PROCTOSONE TEVA-PROCTOSONE
Common or Proper name PROCTOSONE PROCTOSONE
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients DIBUCAINE HYDROCHLORIDE HYDROCORTISONE FRAMYCETIN SULFATE ESCULIN DIBUCAINE HYDROCHLORIDE HYDROCORTISONE FRAMYCETIN SULFATE ESCULIN
Strength(s) 5MG 5MG 10MG 10MG 5MG 5MG 10MG 10MG
Dosage form(s) OINTMENT OINTMENT
Route of administration RECTAL RECTAL
Packaging size 15G 15G
ATC code C05AA C05AA
ATC description AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
Reason for shortage Requirements related to complying with good manufacturing practices. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-07-02 2019-07-02
Estimated end date Unknown 2019-11-30
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Alternate material supplier to be sourced and validated.
Health Canada comments